Literature DB >> 498149

Structure-activity relationships of the antitumor platinum coordination complexes.

T A Connors, M J Cleare, K R Harrap.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 498149

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


× No keyword cloud information.
  13 in total

1.  Analysis of the DNA damage produced by a platinum-acridine antitumor agent and its effects in NCI-H460 lung cancer cells.

Authors:  Xin Qiao; Alexandra E Zeitany; Marcus W Wright; Amal S Essader; Keith E Levine; Gregory L Kucera; Ulrich Bierbach
Journal:  Metallomics       Date:  2012-03-29       Impact factor: 4.526

Review 2.  Synthetic methods for the preparation of platinum anticancer complexes.

Authors:  Justin J Wilson; Stephen J Lippard
Journal:  Chem Rev       Date:  2013-11-27       Impact factor: 60.622

Review 3.  A strategy for the development of two clinically active cisplatin analogs: CBDCA and CHIP.

Authors:  B J Foster; B J Harding; M K Wolpert-DeFilippes; L Y Rubinstein; K Clagett-Carr; B Leyland-Jones
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

4.  In vitro plasma binding of some second generation antitumor platinum complexes.

Authors:  R Momburg; M Bourdeaux; M Sarrazin; F Roux; C Briand
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1985 Jan-Mar       Impact factor: 2.441

5.  Pharmacokinetics of cis-dichloro-trans-dihydroxy-bis-isopropylamine platinum IV (CHIP) in patients with advanced cancer.

Authors:  L Pendyala; W Greco; J W Cowens; S Madajewicz; P J Creaven
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

6.  Resistance and cross-resistance of the IgM immunocytoma in the LOU/M Wsl rat for cisplatin, carboplatin, and iproplatin.

Authors:  P A Steerenberg; C P Vendrik; W H de Jong; G de Groot; A M Fichtinger-Schepman; A P Scheefhals; J H Schornagel
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

7.  Heat enhances the cytotoxicity of cis-diamminedichloroplatinum(II) and its analogues cis-1,1-cyclobutane-dicarboxylato(2R)-2-methyl-1,4- butanediammineplatinum(II) and cis-diammine(glycolato)platinum in vitro.

Authors:  I Takahashi; Y Maehara; H Kusumoto; S Kohnoe; K Sugimachi
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

8.  A non-cross-linking platinum-acridine agent with potent activity in non-small-cell lung cancer.

Authors:  Zhidong Ma; Jayati Roy Choudhury; Marcus W Wright; Cynthia S Day; Gilda Saluta; Gregory L Kucera; Ulrich Bierbach
Journal:  J Med Chem       Date:  2008-12-11       Impact factor: 7.446

9.  Comparative cytotoxicity between cisplatin and second generation platinum analogs.

Authors:  B Drewinko; L Y Yang; J M Trujillo
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

10.  Comparison of the antitumour effects and nephrotoxicity-inducing activities of two new platinum complexes, (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato+ ++)-platinum (II) monohydrate, and its enantiomeric isomer.

Authors:  T Matsumoto; K Endoh; K Akamatsu; K Kamisango; H Mitsui; K Koizumi; K Morikawa; M Koizumi; T Matsuno
Journal:  Br J Cancer       Date:  1991-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.